+86-28-82633987
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
100.9900
2.0000
1.5000
High
90.0000
No
No
No
Yes
No
Positive
10-Methoxycamptothecin (10-MCPT) is a type of plant derived from Camptotheca acuminataand belongs to the camptothecin family of alkaloids. Camptothecin compounds have become an important source for anticancer drug development due to their remarkable antitumor activity. Since Camptothecin (CPT) was first isolated from camptothecin from camptothecin in the 1960s, research on its structural optimization and derivative development has deepened. As a naturally occurring derivative, 10-MCPT has gradually attracted widespread attention from academia and the pharmaceutical industry due to its unique chemical structure and excellent biological activity.
Currently, 10-MCPT has been confirmed to exhibit strong cytotoxicity across various tumor cell lines, especially in ovarian cancer cell line 2774, where its antitumor activity is superior to the structurally similar 10-hydroxycamptothecin. Additionally, recent research suggests that 10-MCPT may play a regulatory role in non-tumor diseases such as acute kidney injury (AKI), involving multiple key molecular targets like HIF1A and HDAC6, broadening its potential therapeutic applications.
This paper will systematically review the chemical structure and physicochemical properties of 10-methoxycamptothecin, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics. Finally, it will explore its clinical application prospects and development trends, aiming to provide a theoretical foundation and reference for further research and drug development of this natural product.
The chemical structure of 10-methoxycamptothecin is based on the classical camptothecin framework, with a molecular formula of C20H19N2O5 and a molecular weight of 378.38. Its structural features mainly include the fusion of a five-membered lactone ring with an indole ring system, where the 10-hydroxyl group is replaced by a methoxy group, forming a 10-methoxy-substituent group. This structural change significantly affects the molecule's polarity, lipid solubility, and ability to bind to targets.
In terms of physicochemical properties, the LogP value of 10-MCPT is about 2.0, indicating moderate lipid solubility, which facilitates membrane penetration and distribution in vivo. The topological pole surface area (TPSA) is 100.99 Ų, indicating a certain polarity that may affect its absorption and blood-brain barrier penetration ability. The number of hydrogen bond acceptors is 7, indicating that it exhibits strong hydrogen bonding forces when binding to biological macromolecules.
Notably, 10-MCPT has a high blood-brain barrier penetration (BBB: High), which opens up potential applications in central nervous system-related diseases. Regarding toxicity assessment, although hepatotoxicity and cardiotoxicity are not yet clear, hERG channel suppression tests are negative, indicating a low risk of cardiotoxicity. However, Ames-induced mutagenic tests were positive, suggesting possible genotoxicity risks and requiring attention and optimization in subsequent drug development.
10-Methoxycamptothecin mainly comes from the bark, leaves, and roots of Camptotheca acuminata. The camphor tree belongs to the genus Nicholas in the Bignoniaceae family, widely distributed in southern China and Southeast Asia. As a traditional Chinese medicinal material, it has a long history. Modern research reveals it contains various alkaloids, among which camptothecin and its derivatives are the most pharmacologically active components.
The extraction of 10-MCPT typically uses solvent extraction combined chromatography separation technology. Common extraction solvents include methanol, ethanol, and their aqueous solutions, which utilize their polarity differences to achieve preliminary separation. Subsequently, further purification was performed using silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC) to obtain high-purity 10-methoxycamptothecin.
In recent years, to improve extraction efficiency and purity, researchers have introduced ultrasound-assisted extraction, microwave-assisted extraction, and high-efficiency membrane separation technologies, significantly shortening extraction time and increasing yield. Additionally, engineering modifications of plant cell culture and biosynthetic pathways have been explored for controlled production of 10-MCPT, aiming to address limited natural resources and environmental impact.
The core pharmacological activity of 10-methoxycamptothecin is its significant antitumor effect. Multiple in vitro cell experiments have shown that 10-MCPT exhibits strong cytotoxicity against ovarian cancer cell line 2774, lung cancer cell line A549, colon cancer cell line HCT116, and others. Compared to 10-hydroxycamptothecin, 10-MCPT shows a lower half-level inhibition concentration (IC50) at the same concentration, suggesting superior anticancer efficacy.
Its antitumor mechanism mainly relies on inhibiting DNA topoisomerase I, blocking DNA replication and transcription processes, and inducing apoptosis in cancer cells. Additionally, 10-MCPT can exert synergistic anticancer effects by activating intracellular apoptosis signaling pathways (such as the caspase family) and inhibiting tumor cell proliferation-related signaling pathways (such as PI3K/Akt).
In addition to its antitumor activity, 10-MCPT has demonstrated certain protective effects in models of acute kidney injury (AKI). The study found that 10-MCPT can regulate various AKI-related molecular targets, including hypoxia-inducing factor 1α (HIF1A), histone deacetylase 6 (HDAC6), endothelin receptor B (EDNRB), mast cell enzyme (CMA1), and adenosine receptor A2B (ADORA2B). These targets play key roles in regulating renal ischemia-reperfusion injury, inflammatory responses, and apoptosis, suggesting that 10-MCPT may alleviate kidney injury through a multi-target co-regulatory mechanism.
Additionally, 10-MCPT has high blood-brain barrier penetration, suggesting its potential application value in neurological diseases, although related research is still in its early stages.
The main mechanism of action of 10-methoxycamptothecin focuses on inhibition of DNA topoisomerase I. Topoisomerase I is an important enzyme for maintaining DNA superhelical structure and replication transcription. 10-MCPT stabilizes the topoisomerase I-DNA complex, preventing DNA strand restoration, leading to DNA breakage and accumulation, which triggers cell cycle arrest and apoptosis.
Beyond its antitumor effects, the regulatory mechanisms of 10-MCPT on targets related to acute kidney injury are gradually elucidating:
HIF1A: As a key transcription factor in hypoxia response, HIF1A regulates cellular adaptation to hypoxic environments. 10-MCPT may alleviate renal hypoxia damage by modulating HIF1A expression or activity.
HDAC6: Involved in cellular stress responses and protein deacetylation, its inhibition helps reduce inflammation and apoptosis. 10-MCPT's regulation of HDAC6 may promote the survival of kidney cells.
EDNRB: Endothelin receptor B is involved in vasoconstriction and cell signal transduction; regulation by 10-MCPT helps improve renal blood flow and function.
CMA1: Mast cell enzymes play a role in inflammatory responses, and 10-MCPT may alleviate inflammatory damage by modulating CMA1.
ADORA2B: The adenosine receptor A2B regulates immune responses and cellular protection; the effects of 10-MCPT help reduce kidney inflammation and apoptosis.
These multi-target mechanisms provide theoretical support for the application of 10-MCPT in non-tumor diseases.
The druggability parameters of 10-methoxycamptothecin indicate that it has certain potential for drug development. Moderate molecular weight (378.38) and LogP (2.0) facilitate oral absorption and distribution of the drug. Higher TPSA and hydrogen bond receptor counts suggest stronger binding ability to target proteins, but may also affect membrane permeability.
Its high blood-brain barrier penetration potential offers possibilities for treating central nervous system diseases, but potential neurotoxicity risks must also be considered. Negative hERG channel inhibition tests reduce the risk of cardiotoxicity, but positive Ames tests suggest genotoxicity risk and require special attention during drug design and safety assessment.
Currently, pharmacokinetic data on 10-MCPT are relatively limited. Previous studies have shown that it has good bioavailability and distribution characteristics in the body, but its metabolic pathways and clearance mechanisms are not yet fully understood. In the future, in vivo and in vitro pharmacokinetic studies are needed to clarify its absorption, distribution, metabolism, and excretion (ADME) characteristics, providing a basis for clinical dosing and administration regimens.
10-Methoxycamptothecin, as an excellent derivative of camptothecin natural products, shows broad application prospects in the field of anti-tumor treatment. Its high cytotoxicity and multi-target mechanism make it an important candidate for developing novel anticancer drugs. Especially in the treatment of solid tumors such as ovarian cancer and lung cancer, 10-MCPT is expected to be used as a monotherapy or in combination to improve treatment efficacy and overcome drug resistance.
Moreover, the potential efficacy of 10-MCPT in non-tumor diseases such as acute kidney injury opens new avenues for its clinical application. By regulating multiple key molecular targets, 10-MCPT may act as a renal protector or adjunct therapy to improve patient outcomes.
However, the genotoxicity risks and safety issues of 10-MCPT still require further research. In the future, toxicological evaluation should be strengthened and molecular structure optimized to reduce potential toxicity. At the same time, systematic pharmacokinetic and pharmacodynamic studies are being conducted to clarify their in vivo behavior and dose-response relationships.
With the development of biosynthesis technology and drug delivery systems, the production process and drug formulations of 10-MCPT are expected to improve, enhancing their clinical feasibility. Combined with precision medicine strategies, personalized medication based on patient molecular characteristics will also become a key research focus in the future.
10-Methoxycamptothecin, as an important derivative of camptothecin natural products, demonstrates strong antitumor potential and multi-target regulatory capability due to its unique chemical structure and significant biological activity. Its emerging applications in diseases such as acute kidney injury further enrich its pharmacological value. Despite safety challenges such as genotoxicity, 10-MCPT still has a solid druggability foundation and potential for clinical translation.
In the future, multidisciplinary collaborative research is needed to deepen understanding of the mechanism of action of 10-MCPT, optimize its drug properties, conduct systematic preclinical and clinical studies, and promote its development into a safe and effective novel anticancer and kidney-protective drug. With continuous advances in natural product pharmacology and drug development technology, 10-methoxycamptothecin is expected to play an increasingly important role in modern medicine.
Shenshuai
Wenjing
Hedandan
